Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, efficacy, and pharmacokinetics of GreenGene F in previously treated patients with severe hemophilia A
2012-001445-40Phase 3Terminated
- Sponsor
- GC Biopharma
- Start
- May 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of GreenGene F in hemophilia A, sponsored by GC Biopharma. Primary endpoints: Incidence of factor VIII inhibitors, Overall safety and 2 more. Started May 2012; status: terminated.
02
Drugs
GreenGene F
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2012-001445-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001445-40.